. 2021 Nov 29;15(11):e0010002. doi: 10.1371/journal.pntd.0010002

Table 3. Immunogenicity of fractional-dose yellow fever vaccine (YFV) in autoimmune rheumatic diseases patients and controls.

	Seroprotection rate, n (%)		GMT, value (95% CI)		Seroconversion rate, n (%)	GMT Factor Increase, value (95% CI)
	Before YFV	After YFV	Before YFV	After YFV	Seroconversion rate, n (%)	GMT Factor Increase, value (95% CI)
ARD (n = 149)	6/149 (4.0) ^*	124/147† (84.3) ^*	31.2 ^* (27.6–35.1)	731.0 ^* (593.6–900.2)	118/141 (83.7) ^*	23.5 (18.5–29.7)
Controls (n = 148)	21/148 (14.2)	135/140^† (96.4)	45.3 (39–52.6)	1143.7 (1012.3–1292.2)	116/120 (96.6)	25.3 (20.6–31)

* p<0.05. Comparison between patients (ARD) and controls

†The samples of 8 controls and 2 ARD patients had indeterminated result of neutralizing antibodies titer measurement at D30.

ARD—autoimmune rheumatic diseases; CI- confidence interval